S&P 500   4,563.66 (-0.67%)
DOW   36,180.95 (-0.18%)
QQQ   385.10 (-1.24%)
AAPL   188.58 (-1.39%)
MSFT   368.52 (-1.60%)
META   318.03 (-2.09%)
GOOGL   128.64 (-2.44%)
AMZN   144.65 (-1.62%)
TSLA   236.62 (-0.93%)
NVDA   454.27 (-2.86%)
NIO   7.30 (+2.10%)
BABA   73.21 (-1.05%)
AMD   118.41 (-2.45%)
T   16.66 (-0.60%)
F   10.72 (+1.32%)
MU   74.12 (-2.38%)
CGC   0.71 (+14.40%)
GE   121.87 (-0.51%)
DIS   92.03 (-0.59%)
AMC   7.16 (+4.37%)
PFE   29.51 (+2.08%)
PYPL   59.90 (+0.42%)
XOM   102.76 (-0.22%)
S&P 500   4,563.66 (-0.67%)
DOW   36,180.95 (-0.18%)
QQQ   385.10 (-1.24%)
AAPL   188.58 (-1.39%)
MSFT   368.52 (-1.60%)
META   318.03 (-2.09%)
GOOGL   128.64 (-2.44%)
AMZN   144.65 (-1.62%)
TSLA   236.62 (-0.93%)
NVDA   454.27 (-2.86%)
NIO   7.30 (+2.10%)
BABA   73.21 (-1.05%)
AMD   118.41 (-2.45%)
T   16.66 (-0.60%)
F   10.72 (+1.32%)
MU   74.12 (-2.38%)
CGC   0.71 (+14.40%)
GE   121.87 (-0.51%)
DIS   92.03 (-0.59%)
AMC   7.16 (+4.37%)
PFE   29.51 (+2.08%)
PYPL   59.90 (+0.42%)
XOM   102.76 (-0.22%)
S&P 500   4,563.66 (-0.67%)
DOW   36,180.95 (-0.18%)
QQQ   385.10 (-1.24%)
AAPL   188.58 (-1.39%)
MSFT   368.52 (-1.60%)
META   318.03 (-2.09%)
GOOGL   128.64 (-2.44%)
AMZN   144.65 (-1.62%)
TSLA   236.62 (-0.93%)
NVDA   454.27 (-2.86%)
NIO   7.30 (+2.10%)
BABA   73.21 (-1.05%)
AMD   118.41 (-2.45%)
T   16.66 (-0.60%)
F   10.72 (+1.32%)
MU   74.12 (-2.38%)
CGC   0.71 (+14.40%)
GE   121.87 (-0.51%)
DIS   92.03 (-0.59%)
AMC   7.16 (+4.37%)
PFE   29.51 (+2.08%)
PYPL   59.90 (+0.42%)
XOM   102.76 (-0.22%)
S&P 500   4,563.66 (-0.67%)
DOW   36,180.95 (-0.18%)
QQQ   385.10 (-1.24%)
AAPL   188.58 (-1.39%)
MSFT   368.52 (-1.60%)
META   318.03 (-2.09%)
GOOGL   128.64 (-2.44%)
AMZN   144.65 (-1.62%)
TSLA   236.62 (-0.93%)
NVDA   454.27 (-2.86%)
NIO   7.30 (+2.10%)
BABA   73.21 (-1.05%)
AMD   118.41 (-2.45%)
T   16.66 (-0.60%)
F   10.72 (+1.32%)
MU   74.12 (-2.38%)
CGC   0.71 (+14.40%)
GE   121.87 (-0.51%)
DIS   92.03 (-0.59%)
AMC   7.16 (+4.37%)
PFE   29.51 (+2.08%)
PYPL   59.90 (+0.42%)
XOM   102.76 (-0.22%)

Gamida Cell Stock Price, News & Analysis (NASDAQ:GMDA)

$0.33
0.00 (-1.48%)
(As of 01:40 PM ET)
Compare
Today's Range
$0.32
$0.33
50-Day Range
$0.25
$1.03
52-Week Range
$0.22
$2.51
Volume
918,505 shs
Average Volume
2.48 million shs
Market Capitalization
$34.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.40

Gamida Cell MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,555.9% Upside
$5.40 Price Target
Short Interest
Bearish
7.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.39mentions of Gamida Cell in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

695th out of 951 stocks

Biological Products, Except Diagnostic Industry

114th out of 159 stocks


GMDA stock logo

About Gamida Cell Stock (NASDAQ:GMDA)

Gamida Cell Ltd. is a biotechnology company specializing in developing and commercializing innovative cell therapies. With a mission to transform the lives of patients with severe hematologic and solid tumor cancers, Gamida Cell is dedicated to harnessing the power of cell therapy to provide effective and personalized treatment options.

Headquartered in Jerusalem, Israel, Gamida Cell operates globally, focusing on developing and delivering breakthrough therapies to address significant unmet medical needs. The company's flagship product, Omidubicel, is an investigational advanced cell therapy designed to enhance the outcome of bone marrow transplantation and improve the standard of care for patients with hematologic malignancies.

Gamida Cell's products and services revolve around cell therapy, with a particular emphasis on expanding and enhancing the therapeutic potential of stem cells. By leveraging its proprietary NAM-based cell expansion technology platform, the company aims to increase the number and functionality of cells for transplantation, leading to improved patient outcomes.

The company primarily targets patients with blood cancers, including leukemia, lymphoma, and myeloma, where traditional treatment options often fall short. Gamida Cell's innovative approach has garnered recognition within the medical community and has received several notable achievements, milestones, and awards. For instance, in 2022, Gamida Cell was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Omidubicel, highlighting the therapy's potential to address a critical medical need.

It is important to note that stock performance is influenced by various factors, including news and events specific to the company. Recent news or events that may have affected Gamida Cell's share price include the publication of clinical trial data, regulatory updates, and announcements regarding partnerships or collaborations.

Looking beyond Gamida Cell's specific performance, it is essential to consider the broader industry in which the company operates. The field of cell therapy has been gaining significant attention and investment in recent years, driven by advancements in technology and the potential to revolutionize the treatment of various diseases, including cancer. Gamida Cell operates in a competitive landscape, with several other companies developing cell therapies and vying for market share.

As part of the industry analysis, it is crucial to evaluate Gamida Cell's competitive positioning and advantages relative to its peers. The company's proprietary NAM-based cell expansion technology platform sets it apart from competitors and positions it as a leader in the field. This technology allows for the expansion and enhancement of cells for transplantation, improving treatment outcomes and addressing critical unmet needs.

Gamida Cell's partnerships and collaborations with established pharmaceutical companies provide validation and access to resources that enhance its competitive advantage. These collaborations enable the company to leverage the expertise and resources of its partners to accelerate the development and commercialization of its cell therapy products.

While Gamida Cell has demonstrated growth and potential, it has risks and challenges. The biotechnology industry is highly regulated, and regulation changes or the regulatory environment can impact the development and approval of new therapies. The company must navigate complex and evolving regulatory pathways to successfully bring its products to market.

Additionally, Gamida Cell faces the challenge of staying ahead of the competition in a rapidly evolving field. Other companies also invest in cell therapies, and competitors' breakthroughs could threaten Gamida Cell's market position. Maintaining a robust research and development pipeline, protecting intellectual property, and securing strategic partnerships are vital for the company's long-term success.

GMDA Stock Price History

GMDA Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Q3 2023 Gamida Cell Ltd Earnings Call
Gamida Cell falls after Q3 revenue miss
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Recap: Gamida Cell Q3 Earnings
Gamida Cell Issues Update on Israel Operations
Pleasing Signs As A Number Of Insiders Buy Gamida Cell Stock
Analyst Ratings for Gamida Cell
See More Headlines
Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.40
High Stock Price Target
$8.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,563.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-79,380,000.00
Pretax Margin
-11,434.03%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.11) per share

Miscellaneous

Free Float
98,492,000
Market Cap
$34.27 million
Optionable
Not Optionable
Beta
1.25
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Ms. Abigail L. Jenkins (Age 47)
    President, CEO & Director
    Comp: $554.05k
  • Ms. Michele Ilene Korfin M.B.A. (Age 51)
    R.Ph., Chief Operating & Chief Commercial Officer
    Comp: $606k
  • Dr. Ronit Simantov M.D. (Age 58)
    Chief Medical Officer & Chief Scientific Officer
    Comp: $592k
  • Mr. Joshua F. Patterson (Age 46)
    General Counsel & Chief Compliance Officer
    Comp: $479k
  • Ms. Mary Theresa Coelho M.B.A. (Age 61)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Ms. Linda Stamler
    Vice President of Marketing & Account Management
  • Ms. Penny Bushell
    Chief Human Resource Officer
  • Mr. Naftali Brikashvili CPA
    Senior Vice President Finance & Operations
  • Dr. Tracey Lodie Ph.D. (Age 53)
    Scientific Advisor & Consultant
  • Mr. Vladimir Melnikov
    Senior Vice President of Global Operations & Manufacturing














GMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings
or view top-rated stocks.

What is Gamida Cell's stock price target for 2024?

5 Wall Street research analysts have issued 12 month price targets for Gamida Cell's stock. Their GMDA share price targets range from $2.00 to $8.00. On average, they expect the company's stock price to reach $5.40 in the next year. This suggests a possible upside of 1,555.9% from the stock's current price.
View analysts price targets for GMDA
or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2023?

Gamida Cell's stock was trading at $1.29 at the beginning of 2023. Since then, GMDA stock has decreased by 74.7% and is now trading at $0.3261.
View the best growth stocks for 2023 here
.

When is Gamida Cell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our GMDA earnings forecast
.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) released its earnings results on Monday, August, 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.13. During the same quarter in the previous year, the company posted ($0.31) earnings per share.

What ETF holds Gamida Cell's stock ?

ARK Israel Innovative Technology ETF holds 1,466,958 shares of GMDA stock, representing 1.97% of its portfolio.

What other stocks do shareholders of Gamida Cell own?
When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (7.62%), Stonepine Capital Management LLC (7.54%), ARK Investment Management LLC (1.34%), Rock Springs Capital Management LP (0.05%), Qube Research & Technologies Ltd (0.03%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends
.

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GMDA) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -